Indication intelligence, analysis and sector perception

Pluristem (PSTI) meets with the U.S. FDA re filing an IND for PLX-R18 to treat Incomplete Hematopoietic Recovery after bone marrow transplantation - SELL

September 9, 2015 12:26pm

A little early for a spike, isn’t it? Successful engraftment of transplanted hematopoietic cells can take … weeks, but in some cases recovery of the bone marrow can be delayed for many … months, or remain … insufficient indefinitely. PSTI closed at $1.90 and is UP in the morning session +$0.07 or +3.68% in a daily range of $1.95 to $1.99 on small 60 K share volume, it never holds value as time and risk/reward always deflates the share pricing.

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

1 hour 2 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.